Core Viewpoint - Boston Scientific shares have increased by approximately 3.3% over the past month, underperforming the S&P 500 index [1] Group 1: Earnings and Estimates - Estimates for Boston Scientific have trended upward in the past month, indicating positive sentiment among analysts [2] - The most recent earnings report highlighted important drivers for the stock's performance [1] Group 2: VGM Scores - Boston Scientific has a Growth Score of B, a Momentum Score of C, and a Value Score of D, placing it in the bottom 40% for the value investment strategy [3] - The aggregate VGM Score for Boston Scientific is C, which is relevant for investors not focused on a single strategy [3] Group 3: Outlook - The upward trend in estimates suggests a promising outlook for Boston Scientific, with a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4] Group 4: Industry Performance - Boston Scientific is part of the Zacks Medical - Products industry, where Abbott has gained 1.6% over the past month [5] - Abbott reported revenues of 0.98 to 1.25 per share, representing a 9.7% increase from the previous year [6]
Boston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue?